[Federal Register Volume 87, Number 9 (Thursday, January 13, 2022)]
[Notices]
[Page 2169]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-00609]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and/or contract proposals 
and the discussions could disclose confidential trade secrets or 
commercial property such as patentable material, and personal 
information concerning individuals associated with the grant 
applications and/or contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Pre-Clinical Medications Discovery and Abuse 
Liability Testing for NIDA (8959).
    Date: January 25, 2022.
    Time: 12:00 p.m. to 1:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Jenny Raye Browning, Ph.D., Scientific Review 
Officer, Scientific Review Branch, Division of Extramural Research, 
National Institute on Drug Abuse, 301 North Stonestreet Avenue, MSC 
6021, Bethesda, MD 20892, (301) 443-4577, <a href="/cdn-cgi/l/email-protection#84eee1eaeafdaae6f6ebf3eaedeae3c4eaedecaae3ebf2"><span class="__cf_email__" data-cfemail="0b616e656572256979647c6562656c4b656263256c647d">[email protected]</span></a>.

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; BRAIN Initiative: Tools for Germline Gene Editing in 
Marmosets (U01--Clinical Trial Not Allowed).
    Date: February 14, 2022.
    Time: 2:00 p.m. to 4:30 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, National Institute 
on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, 
Bethesda, MD 20892, (301) 827-5819, <a href="/cdn-cgi/l/email-protection#690e04585d5c0829070001470e061f"><span class="__cf_email__" data-cfemail="97f0faa6a3a2f6d7f9feffb9f0f8e1">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: January 10, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-00609 Filed 1-12-22; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>